BioMarin Pharmaceutical Inc.
US ˙ NasdaqGS ˙ US09061G1013

SecurityBMRN / BioMarin Pharmaceutical Inc.
InstitutionIFP Advisors, Inc
Latest Disclosed Ownership2,178 shares
Latest Disclosed Value $ 123,035
IFP Advisors, Inc ownership in BMRN / BioMarin Pharmaceutical Inc.

On April 13, 2026 - IFP Advisors, Inc filed a 13F-HR form disclosing ownership of 2,178 shares of BioMarin Pharmaceutical Inc. (US:BMRN) valued at $123,035 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 6, 2026 disclosing 2,090 shares of BioMarin Pharmaceutical Inc.. This represents a change in shares of 4.21% during the quarter. The current value of the position is $119,049 USD.

IFP Advisors, Inc has a history of taking positions in derivatives of the underlying security (BMRN) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

BMRN / BioMarin Pharmaceutical Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-04-13 2026-03-31 13F BIOMARIN PHARMACEUTICAL cs 09061G101 2,178 88 4.21 123 -0.81 0.0026
2026-02-06 2025-12-31 13F BIOMARIN PHARMACEUTICAL cs 09061G101 2,090 -283 -11.93 124 -3.12 0.0028
2026-02-06 2025-09-30 13F/A-1 BIOMARIN PHARMACEUTICAL cs 09061G101 2,373 624 35.68 129 33.33 0.0033
2025-12-02 2025-09-30 13F BIOMARIN PHARMACEUTICAL cs 09061G101 2,373 624 129 0.0033
2025-07-24 2025-06-30 13F BIOMARIN PHARMACEUTICAL cs 09061G101 1,749 1,631 1,382.20 96 1,100.00 0.0027
2025-05-05 2025-03-31 13F BIOMARIN PHARMACEUTICAL cs 09061G101 118 -4,013 -97.14 8 -97.05 0.0003
2025-02-04 2024-12-31 13F BIOMARIN PHARMACEUTICAL cs 09061G101 4,131 1,777 75.49 272 64.24 0.0089
2025-02-04 2024-09-30 13F BIOMARIN PHARMACEUTICAL cs 09061G101 2,354 -189 -7.43 165 -21.05 0.0060
2024-07-30 2024-06-30 13F BIOMARIN PHARMACEUTICAL cs 09061G101 2,543 -27 -1.05 209 -6.70 0.0083
2024-07-30 2024-03-31 13F BIOMARIN PHARMACEUTICAL cs 09061G101 2,570 37 1.46 224 -8.20 0.0098
2024-01-09 2023-12-31 13F BIOMARIN PHARMACEUTICAL cs 09061G101 2,533 865 51.86 244 65.99 0.0115
2023-10-12 2023-09-30 13F BIOMARIN PHARMACEUTICAL cs 09061G101 1,668 -2 -0.12 148 2.08 0.0066
2023-08-14 2023-06-30 13F/A-1 BIOMARIN PHARMACEUTICAL cs 09061G101 1,670 -31 -1.82 145 -7.69 0.0061
2023-08-04 2023-06-30 13F BIOMARIN PHARMACEUTICAL cs 09061G101 1,670 -31 154 0.0071
2023-04-18 2023-03-31 13F BIOMARIN PHARMACEUTICAL cs 09061G101 1,701 -163 -8.74 156 0.0068
2023-02-07 2022-12-31 13F BIOMARIN PHARMACEUTICAL cs 09061G101 1,864 -84 -4.31 0 -100.00 0.0047
2022-11-08 2022-09-30 13F BIOMARIN PHARMACEUTICAL cs 09061G101 1,948 227 13.19 181 13.13 0.0047
2022-09-06 2022-06-30 13F/A-1 BIOMARIN PHARMACEUTICAL cs 09061G101 1,721 0 0.00 160 0.00 0.0051
2022-09-06 2022-03-31 13F/A-1 BIOMARIN PHARMACEUTICAL cs 09061G101 1,721 1,630 1,791.21 160 1,900.00 0.0051
2022-08-08 2022-03-31 13F BIOMARIN PHARMACEUTICAL INC COM Stock 09061G101 1,422 1,331 130 0.0027
2022-01-12 2021-12-31 13F BIOMARIN PHARMACEUTICAL INC COM Stock 09061G101 91 -16 -14.95 8 0.00 0.0002
2021-10-06 2021-09-30 13F BIOMARIN PHARMACEUTICAL INC COM Stock 09061G101 107 -2,200 -95.36 8 -95.85 0.0002
2021-07-13 2021-06-30 13F BIOMARIN PHARMACEUTICAL INC COM Stock 09061G101 2,307 -9 -0.39 193 10.29 0.0040
2021-04-30 2021-03-31 13F BIOMARIN PHARMACEUTICAL INC COM Stock 09061G101 2,316 277 13.59 175 -2.23 0.0034
2021-01-25 2020-12-31 13F BIOMARIN PHARMACEUTICAL INC COM Stock 09061G101 2,039 122 6.36 179 25.17 0.0073
2020-10-29 2020-09-30 13F BIOMARIN PHARMACEUTICAL INC COM Stock 09061G101 1,917 581 43.49 143 -12.27 0.0085
2020-08-05 2020-06-30 13F BIOMARIN PHARMACEUTICAL INC COM Stock 09061G101 1,336 -127 -8.68 163 33.61 0.0129
2020-05-12 2020-03-31 13F BIOMARIN PHARMACEUTICAL INC COM Stock 09061G101 1,463 406 38.41 122 34.07 0.0123
2020-01-17 2019-12-31 13F BIOMARIN PHARMACEUTICAL INC COM Stock 09061G101 1,057 -23 -2.13 91 19.74 0.0068
2019-11-07 2019-09-30 13F BIOMARIN PHARMACEUTICAL INC COM Stock 09061G101 1,080 1,061 5,584.21 76 3,700.00 0.0051
2019-05-15 2019-03-31 13F BIOMARIN PHARMACEUTICALINC Stock 09061G101 19 -203 -91.44 2 -89.47 0.0003
2019-06-03 2018-12-31 13F/A-10 BIOMARIN PHARMACEUTICAL INC COM Stock 09061G101 222 71 47.02 19 26.67 0.0012
2019-01-23 2018-12-31 13F BIOMARIN PHARMACEUTICAL INC COM Stock 09061G101 222 71 19 0.0012
2019-06-03 2018-09-30 13F/A-9 BIOMARIN PHARMACEUTICAL INC COM Stock 09061G101 151 -108 -41.70 15 -37.50 0.0006
2018-10-25 2018-09-30 13F BIOMARIN PHARMACEUTICAL INC COM Stock 09061G101 151 -108 15 0.0006
2019-06-03 2018-06-30 13F/A-8 BIOMARIN PHARMACEUTICAL INC COM Stock 09061G101 259 125 93.28 24 100.00 0.0010
2018-08-07 2018-06-30 13F BIOMARIN PHARMACEUTICAL INC COM Stock 09061G101 259 133 24
2019-06-03 2018-03-31 13F/A-7 BIOMARIN PHARMACEUTICAL INC COM Stock 09061G101 134 0 0.00 12 0.00 0.0005
2018-05-09 2018-03-31 13F BIOMARIN PHARMACEUTICAL INC COM Stock 09061G101 126 -8 10
2019-06-03 2017-12-31 13F/A-6 BIOMARIN PHARMACEUTICAL INC COM Stock 09061G101 134 -383 -74.08 12 -75.00 0.0005
2018-01-24 2017-12-31 13F BIOMARIN PHARMACEUTICAL INC COM Stock 09061G101 134 -383 12
2017-10-30 2017-09-30 13F BIOMARIN PHARMACEUTICAL INC COM Stock 09061G101 517 -4 -0.77 48 2.13 0.0019
2019-06-03 2017-06-30 13F/A-5 BIOMARIN PHARMACEUTICAL INC COM Stock 09061G101 521 62 13.51 47 17.50 0.0020
2017-07-31 2017-06-30 13F BIOMARIN PHARMACEUTICAL INC COM Stock 09061G101 521 62 47
2019-06-03 2017-03-31 13F/A-4 BIOMARIN PHARMACEUTICAL INC COM Stock 09061G101 459 -25 -5.17 40 0.00 0.0017
2017-04-26 2017-03-31 13F BIOMARIN PHARMACEUTICAL INC COM Stock 09061G101 459 -25 40
2019-06-03 2016-12-31 13F/A-3 BIOMARIN PHARMACEUTICAL INC COM Stock 09061G101 484 15 3.20 40 -6.98 0.0019
2017-02-14 2016-12-31 13F BIOMARIN PHARMACEUTICAL INC COM Stock 09061G101 484 15 40
2016-11-04 2016-09-30 13F BIOMARIN PHARMACEUTICAL INC COM Stock 09061G101 469 -78 -14.26 43 0.00 0.0022
2019-06-03 2016-06-30 13F/A-2 BIOMARIN PHARMACEUTICAL INC COM Stock 09061G101 547 528 2,778.95 43 2,050.00 0.0024
2016-08-22 2016-06-30 13F BIOMARIN PHARMACEUTICAL INC COM Stock 09061G101 547 528 43
2019-06-03 2016-03-31 13F/A-1 BIOMARIN PHARMACEUTICALINC Stock 09061G101 19 -394 -95.40 2 -95.35 0.0003
2016-05-02 2016-03-31 13F BIOMARIN PHARMACEUTICAL INC COM Stock 09061G101 793 380 65
2016-02-11 2015-12-31 13F BIOMARIN PHARMACEUTICAL INC COM Stock 09061G101 413 413 43 0.0029
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2019-06-03 2018-09-30 13F/A BIOMARIN PHARMACEUTICAL INC COM Stock Call 0 -100.00 0 -100.00 n/a n/a n/a
2019-06-03 2018-06-30 13F/A BIOMARIN PHARMACEUTICAL INC COM Stock Call 100 9 n/a n/a n/a
2018-08-07 2018-06-30 13F BIOMARIN PHARMACEUTICAL INC COM Stock Call 100 9 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.